Supplementary Figure S5.



Supplementary Figure S5. Combination of olaparib and crizotinib induces ROS, DNA damage and apoptosis in ovarian cancer cells. (A) Evaluation of ROS formation. Cells were plated in 6-well plates in triplicate and treated with olaparib (5uM) and crizotinib (1uM) for 48 hrs. Cells were stained with 5 mM H2DCFDA, collected and analyzed by flow cytometry after 30 minutes incubation. ROS formation is represented as mean fluorescence intensity. Data represent the mean of 1 independent experiment with three replicates. Results were obtained using one-way ANOVA. *p< 0.05, **p<0.01, ***p<0.001, ****P<0.0001. Error bars represent means ± SD. **(B)** Western blot analysis and fluorescence staining **(C)** were performed to evaluate expression of ɣ-H2AX. SKOv3, HEY and OVCAR3 ovarian cancer cells were treated with olaparib (5 µM), crizotinib (1µM) or both for 5 days. **(D)** Cells were labeled with PI/Annexin V-FITC and analyzed for apoptosis using flow cytometry. Error bars represent mean ± SD.